Yes. Several have pointed to September-ish. I personally think that while possible, it is optimistic (early).
Phase 3 trials for EDP-235 needs to be started by late fall to early winter to be ready for a likely surge of cases then, well assuming Covid becomes more of a seasonal disease like influenza and RSV. To be ready, you know ENTA has been/is engaged with the FDA to lay out plans for the trials so they will get a decent handle on the costs. A partnership needs to be in place by then. If ENTA isn't finding the kind of terms they deem acceptable then they will have to considered running it alone. I know that isn't what they or I want as it is a bigger risk, but if it has to be done, then so be it.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.